The US Food and Drug Administration is coming up with a process to change the composition of COVID-19 vaccines as their effectiveness declines over time. But many questions remain unresolved, such as when it is clear current vaccines are providing insufficient protection and if manufacturers will be able to alter the strains fast enough to have an impact.
The agency’s Vaccines and Related Biological Products Advisory Committee considered these issues at its 6 April meeting
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?